1.42
price up icon0.00%   0.00
 
loading
Maxcyte Inc stock is traded at $1.42, with a volume of 2.01M. It is up +0.00% in the last 24 hours and down -36.61% over the past month. MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
See More
Previous Close:
$1.42
Open:
$1.43
24h Volume:
2.01M
Relative Volume:
2.23
Market Cap:
$151.38M
Revenue:
$45.44M
Net Income/Loss:
$-35.43M
P/E Ratio:
-4.1765
EPS:
-0.34
Net Cash Flow:
$-25.39M
1W Performance:
+4.41%
1M Performance:
-36.61%
6M Performance:
-63.12%
1Y Performance:
-65.53%
1-Day Range:
Value
$1.40
$1.48
1-Week Range:
Value
$1.34
$1.48
52-Week Range:
Value
$1.26
$5.20

Maxcyte Inc Stock (MXCT) Company Profile

Name
Name
Maxcyte Inc
Name
Phone
301-517-5556
Name
Address
9713 KEY WEST AVENUE,, ROCKVILLE
Name
Employee
114
Name
Twitter
Name
Next Earnings Date
2025-03-11
Name
Latest SEC Filings
Name
MXCT's Discussions on Twitter

Compare MXCT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Medical Devices icon
MXCT
Maxcyte Inc
1.42 149.25M 45.44M -35.43M -25.39M -0.34
Medical Devices icon
ABT
Abbott Laboratories
132.59 226.73B 43.11B 13.94B 6.78B 7.98
Medical Devices icon
BSX
Boston Scientific Corp
106.17 152.69B 18.49B 2.50B 3.49B 1.68
Medical Devices icon
SYK
Stryker Corp
394.22 145.89B 23.82B 2.92B 4.02B 7.55
Medical Devices icon
MDT
Medtronic Plc
92.71 118.91B 33.54B 4.69B 5.19B 3.62
Medical Devices icon
EW
Edwards Lifesciences Corp
81.83 45.97B 5.69B 1.41B 577.90M 6.95

Maxcyte Inc Stock (MXCT) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-11-25 Downgrade BTIG Research Buy → Neutral
Aug-07-25 Downgrade William Blair Outperform → Mkt Perform
Jul-22-25 Initiated Stephens Overweight
Nov-29-23 Initiated Craig Hallum Buy
Oct-15-21 Resumed Cowen Outperform
Aug-24-21 Initiated BTIG Research Buy
Aug-24-21 Initiated Cowen Outperform
Aug-24-21 Initiated Stephens Overweight
Aug-24-21 Initiated Stifel Buy
Aug-24-21 Initiated Wedbush Outperform
Aug-24-21 Initiated William Blair Outperform
View All

Maxcyte Inc Stock (MXCT) Latest News

pulisher
Aug 20, 2025

Quant Models Detect Momentum Reversal in MaxCyte Inc.Quarterly Trade Review & High Conviction Trade Alerts - newsyoung.net

Aug 20, 2025
pulisher
Aug 18, 2025

MaxCyte Inc. Rebound Backed by Sentiment ShiftPrice Action & Fast Moving Stock Trade Plans - beatles.ru

Aug 18, 2025
pulisher
Aug 17, 2025

What makes MaxCyte Inc. stock price move sharplyJuly 2025 Chart Watch & Weekly High Return Forecasts - classian.co.kr

Aug 17, 2025
pulisher
Aug 17, 2025

MaxCyte Inc. Testing Reversal Zone on Weekly ChartWeekly Trade Review & Fast Gain Swing Trade Alerts - metal.it

Aug 17, 2025
pulisher
Aug 15, 2025

MaxCyte Signs Platform License Agreement With Adicet Bio - Technology Networks

Aug 15, 2025
pulisher
Aug 14, 2025

What machine learning models say about MaxCyte Inc.IPO Watch & Reliable Breakout Forecasts - Newser

Aug 14, 2025
pulisher
Aug 14, 2025

Why MaxCyte Inc. is moving todayJuly 2025 Catalysts & Free Safe Entry Trade Signal Reports - Newser

Aug 14, 2025
pulisher
Aug 14, 2025

What MACD and RSI say about MaxCyte Inc.2025 Biggest Moves & Fast Moving Market Watchlists - Newser

Aug 14, 2025
pulisher
Aug 14, 2025

Analyzing the Impact of Earnings Reports on MaxCyte Inc Inc. (MXCT) Price Performance - investchronicle.com

Aug 14, 2025
pulisher
Aug 14, 2025

Signal strength of MaxCyte Inc. stock in tech scannersWeekly Trade Analysis & Capital Efficiency Focused Ideas - Newser

Aug 14, 2025
pulisher
Aug 14, 2025

Maxcyte Stock Soars 10.87% on Insider Buying - AInvest

Aug 14, 2025
pulisher
Aug 14, 2025

Volume spikes in MaxCyte Inc. stock – what they meanIPO Watch & Weekly Top Stock Performers List - Newser

Aug 14, 2025
pulisher
Aug 13, 2025

Custom strategy builders for tracking MaxCyte Inc.Treasury Yields & Safe Swing Trade Setup Alerts - Newser

Aug 13, 2025
pulisher
Aug 13, 2025

Douglas buys $111k in Maxcyte shares By Investing.com - Investing.com South Africa

Aug 13, 2025
pulisher
Aug 13, 2025

Masoud Maher buys Maxcyte (MXCT) shares worth $102,915 - Investing.com

Aug 13, 2025
pulisher
Aug 13, 2025

Masoud Maher buys Maxcyte (MXCT) shares worth $102,915 By Investing.com - Investing.com Nigeria

Aug 13, 2025
pulisher
Aug 13, 2025

Brooke William buys Maxcyte (MXCT) shares worth $64,500 By Investing.com - Investing.com Canada

Aug 13, 2025
pulisher
Aug 13, 2025

Maxcyte CFO Swirsky buys $64.5k in shares By Investing.com - Investing.com Canada

Aug 13, 2025
pulisher
Aug 13, 2025

Erck Stanley C, Maxcyte director, buys $137k in MXCT stock - Investing.com Canada

Aug 13, 2025
pulisher
Aug 13, 2025

Maxcyte CFO Swirsky buys $64.5k in shares - Investing.com

Aug 13, 2025
pulisher
Aug 13, 2025

Brooke William buys Maxcyte (MXCT) shares worth $64,500 - Investing.com India

Aug 13, 2025
pulisher
Aug 13, 2025

Maxcyte Director and CFO Make Significant Stock Purchases. - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

Should value investors consider MaxCyte Inc.Game-Changing Investment Alerts - thegnnews.com

Aug 13, 2025
pulisher
Aug 13, 2025

Will MaxCyte Inc. continue its uptrendJuly 2025 Trends & Stepwise Trade Signal Implementation - Newser

Aug 13, 2025
pulisher
Aug 13, 2025

MaxCyte (NASDAQ:MXCT) Earns Neutral Rating from BTIG Research - Defense World

Aug 13, 2025
pulisher
Aug 13, 2025

MaxCyte Inc. Breaks Losing Streak — Is the Trend ReversingFree Premium Stock Market Reports - beatles.ru

Aug 13, 2025
pulisher
Aug 11, 2025

Chart based exit strategy for MaxCyte Inc.Oversold Stock Bounce Playbook Generator - Newser

Aug 11, 2025
pulisher
Aug 11, 2025

Chartists Watching For Breakout in MaxCyte Inc.Weekly Return Pick Forecast Reports Show Trend - beatles.ru

Aug 11, 2025
pulisher
Aug 11, 2025

MaxCyte Chief Commercial Officer Departs Amid Severance Agreement - TipRanks

Aug 11, 2025
pulisher
Aug 11, 2025

BTIG Downgrades MaxCyte to Neutral Citing Ongoing Challenges for Cell and Gene Therapy Customers - AInvest

Aug 11, 2025
pulisher
Aug 11, 2025

MaxCyte Shares Plummet After Analyst Downgrades and Missed Earnings Estimates - AInvest

Aug 11, 2025
pulisher
Aug 11, 2025

MaxCyte Shares Fall After BTIG Downgrade - MarketScreener

Aug 11, 2025
pulisher
Aug 11, 2025

MaxCyte Signs Strategic Platform License with Adicet Bio for Cancer and Autoimmune Diseases Treatments. - AInvest

Aug 11, 2025
pulisher
Aug 11, 2025

MaxCyte (MXCT) Signed a Strategic Platform License with Adicet Bio - Yahoo Finance

Aug 11, 2025
pulisher
Aug 11, 2025

This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday - Benzinga

Aug 11, 2025
pulisher
Aug 11, 2025

BTIG Downgrades MaxCyte to Neutral From Buy - MarketScreener

Aug 11, 2025
pulisher
Aug 11, 2025

MaxCyte stock rating downgraded to Neutral by BTIG on funding concerns - Investing.com South Africa

Aug 11, 2025
pulisher
Aug 11, 2025

MaxCyte signs platform license agreement with Adicet Bio for Gamma Delta T cell therapies - SelectScience

Aug 11, 2025
pulisher
Aug 11, 2025

BTIG Downgrades Maxcyte Neutral from Buy Rating - AInvest

Aug 11, 2025
pulisher
Aug 09, 2025

MaxCyte signs platform license agreement with Adicet Bio - MSN

Aug 09, 2025
pulisher
Aug 09, 2025

Is MaxCyte Inc. Forming a Consolidation BaseMarket Surge Signal for Swing Traders Triggered - beatles.ru

Aug 09, 2025
pulisher
Aug 09, 2025

MaxCyte (NASDAQ:MXCT) Lowered to Sell Rating by Wall Street Zen - Defense World

Aug 09, 2025
pulisher
Aug 08, 2025

MaxCyte Inc Q2 2025 Earnings: Revenue Falls Short at $8.5 Million, Net Loss Widens to $12.4 Million - AInvest

Aug 08, 2025
pulisher
Aug 08, 2025

MaxCyte, Inc. (NASDAQ:MXCT) Q2 2025 Earnings Call Transcript - Insider Monkey

Aug 08, 2025
pulisher
Aug 07, 2025

Maxcyte, Inc. shares rise 1.40% after-hours despite William Blair downgrading to Market Perform. - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

MaxCyte, Inc. (MXCT) Reports Q2 Loss, Misses Revenue Estimates - MSN

Aug 07, 2025
pulisher
Aug 07, 2025

MaxCyte revises 2025 core revenue guidance to $29.5M-$32.5M amid customer program consolidation - MSN

Aug 07, 2025
pulisher
Aug 07, 2025

Maxcyte's 31% Intraday Plunge: Earnings Woes and Sector Turbulence Spark Investor Panic - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

MaxCyte Disappoints With Lower Revenue And Guidance For 2025 - Finimize

Aug 07, 2025
pulisher
Aug 07, 2025

William Blair Downgrades MaxCyte to Market Perform From Outperform - MarketScreener

Aug 07, 2025
pulisher
Aug 07, 2025

MaxCyte downgraded to Market Perform from Outperform at William Blair - TipRanks

Aug 07, 2025

Maxcyte Inc Stock (MXCT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Maxcyte Inc Stock (MXCT) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Masoud Maher
President and CEO
Aug 13 '25
Buy
1.37
75,000
102,915
175,000
Erck Stanley C
Director
Aug 13 '25
Buy
1.37
100,000
137,220
398,328
DOUGLAS RICHARD
Director
Aug 13 '25
Buy
1.39
80,000
111,040
230,577
Brooke William W
Director
Aug 13 '25
Buy
1.29
50,000
64,500
150,879
$330.77
price up icon 0.89%
medical_devices STE
$251.87
price up icon 1.77%
medical_devices PHG
$28.34
price up icon 3.28%
$82.26
price up icon 2.03%
$75.22
price up icon 2.83%
medical_devices EW
$81.83
price up icon 0.83%
Cap:     |  Volume (24h):